Research programme: glucagon-like peptide-2 analogues - TheratechnologiesAlternative Names: TH 0312
Latest Information Update: 19 Mar 2008
At a glance
- Originator Theratechnologies
- Class Peptides
- Mechanism of Action Glucagon-like peptide 2 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammatory bowel diseases